Zevra Therapeutics Inc (NASDAQ: ZVRA) stock jumped 1.40% on Friday to $4.34 against a previous-day closing price of $4.28. With 0.18 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.15 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.4300 whereas the lowest price it dropped to was $4.2300. The 52-week range on ZVRA shows that it touched its highest point at $6.44 and its lowest point at $3.89 during that stretch. It currently has a 1-year price target of $19.33. Beta for the stock currently stands at 1.90.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZVRA was up-trending over the past week, with a rise of 4.58%, but this was down by -0.69% over a month. Three-month performance dropped to -14.23% while six-month performance fell -19.63%. The stock lost -1.14% in the past year, while it has lost -5.45% so far this year. A look at the trailing 12-month EPS for ZVRA yields -1.16 with Next year EPS estimates of -1.01. For the next quarter, that number is -0.28. This implies an EPS growth rate of -1.04% for this year and 16.91% for next year.
Float and Shares Shorts:
At present, 34.54 million ZVRA shares are outstanding with a float of 32.88 million shares on hand for trading. On Oct 30, 2023, short shares totaled 2.28 million, which was 6.29% higher than short shares on Sep 28, 2023. In addition to Mr. R. LaDuane Clifton CPA as the firm’s CFO, Secretary & Treasurer, Mr. Neil F. McFarlane serves as its President, CEO & Director.
Through their ownership of 19.80% of ZVRA’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.41% of ZVRA, in contrast to 18.42% held by mutual funds. Shares owned by individuals account for 13.82%. As the largest shareholder in ZVRA with 6.37% of the stake, Nantahala Capital Management LLC holds 2,308,216 shares worth 2,308,216. A second-largest stockholder of ZVRA, BlackRock Fund Advisors, holds 1,965,494 shares, controlling over 5.43% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in ZVRA, holding 1,586,135 shares or 4.38% stake. With a 2.67% stake in ZVRA, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 967,269 shares are owned by the mutual fund manager. The iShares Russell 2000 ETF, which owns about 2.16% of ZVRA stock, is the second-largest Mutual Fund holder. It holds 783,169 shares valued at 3.51 million. HealthInvest Small & Micro Cap Fu holds 1.85% of the stake in ZVRA, owning 670,000 shares worth 3.0 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZVRA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With ZVRA analysts setting a high price target of $24.00 and a low target of $12.00, the average target price over the next 12 months is $19.33. Based on these targets, ZVRA could surge 453.0% to reach the target high and rise by 176.5% to reach the target low. Reaching the average price target will result in a growth of 345.39% from current levels.
Summary of Insider Activity:
Insiders traded ZVRA stock several times over the past three months with 4 Buys and 0 Sells. In these transactions, 21,500 shares were bought while 0 shares were sold. The number of buy transactions has increased to 28 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 77,819 while 0 shares were sold.